Rx Drug Promotion Studies Target Biosimilar Disclosures, Unapproved Uses, Multiple Indications

 
• By Brenda Sandburg

US FDA proposes studies to look at the impact of disclosure of a product’s secondary claims and biosimilar designation; disclosure about unapproved uses; and the impact of citing a drug’s multiple indications in TV ads.

Conceptual business illustration with the words direct-to-consumer advertising
FDA proposes three new studies of Rx drug promotion • Source: Shutterstock

More from Marketing & Advertising

More from Compliance